NEW YORK (GenomeWeb) – GenMark Diagnostics reported after the close of the market on Monday that its first quarter revenues rose 80 percent, driven in part by continued sales growth of its ePlex molecular diagnostics analyzer and by its SARS-CoV-2 test.
The company also announced interim CEO Scott Mendel had been appointed President and CEO.